Underreporting of adverse reaction. A current problem of Drug Surveillance?

Authors

DOI:

https://doi.org/10.5281/zenodo.14908365

Keywords:

adverse reactions, Pharmacovigilance

Abstract

Drugs are one of the products widely used worldwide in practically all diseases, which has given them a leading role in modern medicine. Despite their beneficial effects, they are capable of causing damage to health, and even death.


An adverse drug reaction (ADR) is defined as any unwanted effect that occurs at normal doses after the administration of a product used to prevent, diagnose or treat any disease. It can occur at any time and regardless of the number of doses.

In Pharmacovigilance, spontaneous reporting of suspected ADRs is the most used method to identify new safety problems. This is simple and low-cost, and it also allows monitoring of ADRs without interfering with prescription habits. Although an increase in annual ADR notification rates is observed in Cuba, the existence of under-reporting of ADRs stands out. This decreases the sensitivity of the method, may delay the detection of new signals, and make the system more sensitive to selective reporting.

References

Tarragó Portelles SS, Gravier Hernández R, Gil del Valle L. La Farmacovigilancia en Cuba y la Infranotificaciones de Reacciones Adversas a los Medicamentos. Horizonte Sanitario. 2019 [citado 18/05/2021];18(1):7-15.Disponible en: https://revistas.ujat.mx/index.php/horizonte/article/view/2514

Morón RF. Farmacología General .La Habana: Ciencias Médicas; 2002.

Montané E, Santesmases J. Adverse drug reactions. Med Clín(Barc). 2020 [citado 21/08/2020]; 154(5):178-184. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S2387020620300371

Rojas Pérez S, Benítez Rojas LC, Rua del Toro M, Espinosa Palacio D, Gallardo Pedraza AM. Cinco años en el registro de reacciones adversas a fitofármacos notificadas en Las Tunas. Rev Electron Zoilo. 2019 [citado 16/08/2021];44(5). Disponible en: http://revzoilomarinello.sld.cu/index.php/zmv/article/view/1982

Rúa del Toro M, Benitez Rojas LC, Rojas Pérez SC, Pupo Pérez Y. Reacciones adversas a los analgésicos no opioides notificadas en Las Tunas, 2017 hasta primer semestre de 2019. Rev Electron Zoilo.2020 [citado 16/08/2021]; 45(6).Disponible en: http://revzoilomarinello.sld.cu/index.php/zmv/article/view/2490

Jiménez López G, Alfonso Orta I, Robaina González R, Borrero Coss NO, Mosqueda Gorina C, Portuondo Sánchez C. Vigilancia activa centrada en el paciente desde la Autoridad Reguladora Nacional de Medicamentos. Convención Internacional de Salud, Cuba Salud; 2018/04/23-27.La Habana: Palacio de las Convenciones; 2018.Disponible en: http://www.convencionsalud2018.sld.cu/index.php/connvencionsalud/2018/paper/viewPDFInterstitial/1208/376

Nogareda Moreno F, Díaz Roselló B. Causas de Infranotificación de reacciones adversas a medicamentos en la comunidad autónoma de las Islas Baleares. Medicina Balear. 2006 [citado 18/05/2021];21(2) 42-45. Disponible en: https://dialnet.unirioja.es/servlet/articulo?codigo=6371127

Published

2021-09-09 — Updated on 2021-09-09

How to Cite

1.
Benítez Rojas L de la C. Underreporting of adverse reaction. A current problem of Drug Surveillance?. Rev. estud. HolCien [Internet]. 2021 Sep. 9 [cited 2025 Aug. 21];2(2):e125. Available from: https://revholcien.sld.cu/index.php/holcien/article/view/125

Issue

Section

EDITORIAL